| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT04332367 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… |
date change Primary completion pushed: 2026-04 -> 2026-09-30 |
| 2026-06-11 | NCT04332367 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… |
date change Completion pushed: 2026-04 -> 2026-09-30 |
| 2026-06-04 | NCT05642572 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has… |
date change Primary completion pushed: 2026-05-31 -> 2027-06-30 |
| 2026-06-04 | NCT05642572 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has… |
date change Completion pushed: 2027-05-31 -> 2028-06-30 |
| 2026-05-28 | NCT07098338 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) |
Trial sites expanded: 64 -> 83 locations |
| 2026-05-23 | NCT03527108 Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC |
date change Primary completion pushed: 2026-04 -> 2026-12 |
| 2026-05-19 | NCT07546812 Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With… |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-18 | NCT07594548 Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated… | Metastatic Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent… | Recurrent Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or… | Gastric Cancer, Adenocarcinoma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT06616584 | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced… | Recurrent Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal… | Advanced Esophageal Adenocarcinoma | Recruiting |
| NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or… | Advanced Gastric or EGJ Cancer | Active, Not Recruiting |
| NCT05096663 | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus… | Advanced Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05999994 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children… | Neoplasms | Recruiting |
| NCT06031688 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14… | Recurrent Lung Non-Small Cell Carcinoma | Recruiting |
| NCT07546812 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With… | HER2-negative | Recruiting |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | Recruiting |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has… | Recurrent Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06043427 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT04332367 | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… | Non-small Cell Lung Cancer | Recruiting |
| NCT06448754 | Volrustomig Priming Regimens Exploratory Phase II Platform Study | Non-small Cell Lung Cancer | Recruiting |
| NCT04340882 | Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on… | Metastatic Non-Small Lung Cell Cancer | Active, Not Recruiting |
| NCT05980000 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and… | Recurrent Head and Neck Cancer | Active, Not Recruiting |
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and… | Metastatic Esophageal Carcinoma | Active, Not Recruiting |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04310007 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune… | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06007937 | A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | Non Small Cell Lung Cancer | Recruiting |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma… | Gastroesophageal Junction | Recruiting |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With… | Solid Cancer | Active, Not Recruiting |